Lucira Health, Inc.
We are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. We developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. We believe the novel coronavirus, or COVID-19, pandemic has shown the infectious disease testing infrastructure in the United States was not designed to accommodate the immediate demands of infectious disease control on a mass-population scale. The testing options today are too expensive, inaccurate, or are inaccessible due to slow time to results or complexity. Our LUCIRA COVID-19 All-In-One Test Kit, or our COVID-19 test kit, is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. Our initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications.
On Nov. 17, 2020, we received an Emergency Use Authorization from the FDA for (1) prescription at-home use with self-collected nasal swab specimens in individuals aged 14 and older who are suspected of COVID-19 by their healthcare provider and (2) use at the point-of-care with self-collected nasal swab specimens in individuals aged 14 and older, and in individuals aged 13 and under when the specimen is collected by a healthcare provider at the point of care.
(Note: Lucira Health upsized its IPO at pricing on Feb. 4, 2021: 9 million shares at $17 – up from 7.81 million shares at $15 to $17 in the prospectus – to raise $153 million; this IPO was priced at the top of its range.)
|Industry:||In vitro & in vivo diagnostic substances|
|Address||1412 62nd Street Emeryville, California 94608|
|Phone Number||(510) 350-8071|
|View Prospectus:||Lucira Health, Inc.|
|Revenues||$0.27 mil (last 12 months)|
|Net Income||$-22.3 mil (last 12 months)|
|Price range||$17.00 - $17.00|
|Est. $ Volume||$153.0 mil|
|Manager / Joint Managers||BofA Securities/ William Blair/ LifeSci Capital|
|Expected To Trade:||2/5/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|